Endpoint surrogacy in oncology Phase 3 randomised controlled trials
Jianrong Zhang, Meagan Pilar, Xiaofei Wang, Jingxia Liu, Herbert Pang, Ross C. Brownson, Graham A. Colditz, Wenhua Liang, Jianxing He
Abstract
Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint-instead of overall survival-would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the newly approved drugs.
Topics & Concepts
Clinical endpointSurrogate endpointMedicineOncologyInternal medicineEndpoint DeterminationClinical trialDrug approvalProgression-free survivalCancer drugsOverall survivalCancerDrugPharmacologyStatistical Methods in Clinical TrialsCancer Genomics and DiagnosticsPharmacogenetics and Drug Metabolism